4-氨基苯丙炔酸 | 35283-05-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基苯丙炔酸
• 英文名称: p-aminophenylpropiolic acid
• 英文别名: 4-Aminophenyl-propinsaeure；(4-amino-phenyl)-propiolic acid；(4-Amino-phenyl)-propiolsaeure；3-(4-Aminophenyl)prop-2-ynoic acid
• CAS: 35283-05-7
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: RWFWFVMXYURNLS-UHFFFAOYSA-N

物化性质

• 熔点：
  200-210 °C (decomp)
• 沸点：
  384.9±34.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基苯丙炔酸 、 水 生成 4-氨基苯乙酮
  参考文献：
  名称：

  Granados; Alonso Cermeno, Anales de la Real Sociedad Espanola de Fisica y Quimica, 1956, vol. 52, p. 359

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(4-硝基苯基)丙-2-炔酸 在 ammonium iron(II) sulfate 、 ammonium hydroxide 作用下， 生成 4-氨基苯丙炔酸
  参考文献：
  名称：

  Granados; Alonso Cermeno, Anales de la Real Sociedad Espanola de Fisica y Quimica, 1956, vol. 52, p. 359

  摘要：

  DOI：

文献信息

• Central Doping of a Foreign Atom into the Silver Cluster for Catalytic Conversion of CO₂ toward C−C Bond Formation
  作者：Yuanyuan Liu、Xiaoqi Chai、Xiao Cai、Mingyang Chen、Rongchao Jin、Weiping Ding、Yan Zhu

  DOI：10.1002/anie.201805319

  日期：2018.7.26

  with an exact number of atoms are of particular interest in catalysis. Their catalytic behaviors can be potentially altered with the addition or removal of a single atom. Now the effects of doping with a single foreign atom (Au, Pd, and Pt) into the core of an Ag cluster with 25 atoms on the catalytic properties are explored, where the foreign atom is protected by 24 Ag atoms (Au@Ag24, Pd@Ag24, and

  在催化中，具有确切原子数的簇特别受关注。它们的催化行为可以通过添加或去除单个原子来潜在地改变。现在，研究了用单个外来原子（Au，Pd和Pt）掺杂到具有25个原子的Ag团簇的核中对催化性能的影响，其中外来原子受24个Ag原子保护（Au @ Ag 24，Pd @ Ag 24和Pt @ Ag 24）。单个原子向Ag 25团簇的中心掺杂对CO 2羧化反应中的催化性能有很大影响。与末端炔烃通过C-C键形成而生成丙酸。这些研究表明，通过远离活性中心的单个原子的细微变化，簇状催化剂的催化性能会发生显着变化。
• Practical Synthesis of Unsymmetrical Diarylacetylenes from Propiolic Acid and Two Different Aryl Bromides
  作者：Stefano Tartaggia、Ottorino De Lucchi、Lukas J. Gooßen

  DOI：10.1002/ejoc.201101770

  日期：2012.3

  A palladium catalyst that mediates the one-pot sequential Sonogashira and decarboxylative coupling of propiolic acid with two different aryl bromides has been developed. Selective coupling of the first aryl bromide was achieved in the presence of a copper-free, monometallic catalyst generated in situ from allylpalladium chloride dimer and SPhos with tetra-n-butylammonium fluoride as the base in an

  已开发出一种钯催化剂，可介导丙炔酸与两种不同的芳基溴化物的一锅顺序 Sonogashira 和脱羧偶联。在由烯丙基氯化钯二聚体和 SPhos 以四正丁基氟化铵为碱在 N-甲基-2-吡咯烷酮/水中原位生成的无铜单金属催化剂存在下，实现了第一个芳基溴化物的选择性偶联溶剂混合物。在加入另一种芳基溴并将温度从 50°C 升高到 80°C 后，中间体芳基丙炔酸进行脱羧偶联得到相应的二芳基乙炔。因此，新系统允许从广泛使用的芳基溴化物而不是昂贵的芳基碘化物和丙炔酸一锅三组分合成不对称二芳基乙炔，而不是（三甲基甲硅烷基）乙炔，作为一种廉价且易于处理的乙炔合成子。该过程具有高度选择性、模块化，并且可以以良好的收率获得各种不对称二芳基乙炔。
• Release of Terminal Alkynes via Tandem Photodeprotection and Decarboxylation of <i>o</i>-Nitrobenzyl Arylpropiolates in a Flow Microchannel Reactor
  作者：Behabitu Ergette Tebikachew、Karl Börjesson、Nina Kann、Kasper Moth-Poulsen

  DOI：10.1021/acs.bioconjchem.7b00812

  日期：2018.4.18

  reaction. Furthermore, the effect of different substituents (methyl, vinyl, allyl, and phenyl) at the benzylic position on the rate of photodeprotection was studied. The quantum yields of photolysis for the benzylic-substituted esters were determined to be as high as 0.45 compared to the unsubstituted ester with a 0.08 quantum yield of photolysis.

  与传统的保护基团相比，可光裂解的保护基团（PPG）提供了互补的保护范式。在本文中，使用邻硝基苄基（NB）PPG来保护各种芳基丙酸。在微通道反应器中级联触发光触发的光脱保护（停留时间为100-500 s），然后在60°C下进行Cu催化的脱羧反应，NB保护的芳基丙酸提供了末端炔。该末端炔烃在原位进一步反应一键反应通过叠氮化物与叠氮化物通过点击化学反应生成1,2,3-三唑。此外，研究了苄基位置上不同取代基（甲基，乙烯基，烯丙基和苯基）对光脱保护速率的影响。经测定，与未取代的酯相比，苄基取代的酯的光解量子产率高达0.45，光解的量子产率为0.08。
• Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0003663A2

  公开（公告）日：1979-08-22

  The invention provides novel amino-substituted phenyl and heteroaryl compounds which show pharmaceutically useful properties, particularly as hypolipidemic and antiatherosclerotic agents, and processes for the preparation of the novel compounds. The novel compounds have the formula: Q is wherein Y is loweralkyl, loweralkoxy, hydroxy, nitro, acyloxy or halo, and m is an integer of from 0 to 4 inclusive, or a 5- or 6-membered heteroaryl ring containing 1 or more nitrogen, sulfur or oxygen atoms and which may be optionally substituted with one fluorine atom; R is hydrogen or a group convertible in vivo thereinto; Z is: wherein J is selected from the group consisting of hydroxy, loweralkoxy, loweralkoxyloweralkyloxy, diloweralkylaminoloweralkoxy, hydrogen, loweralkyl, (mono-or polyhydroxy)loweralkoxy, (mono- or polycarboxy)loweralkoxy, (mono- or polycarboxy)hydroxyloweralkoxy, allyloxy, 2,3-epoxypropoxy, substituted or unsubstituted(phen- oxy, benzyloxy and 3-pyridyloxy), pyridylmethoxy, tetra- hydropyranyloxy, (mono- or polyhydroxyl)loweralkyl- amino, (mono- or polycarboxy)loweralkylamino, (mono-or polycarboalkoxy)loweralkylamino, allylamino, propargylamino, 2-sulfoethylamino. (substituted or unsubstituted aroyl)amino, loweralkanoylamino, loweralkanesulfonylamino, (substituted or unsubstituted arene)sulfonylamino, loweralkanoylhydrazino, hydroxylamino, polymethyleneimino, (4-carboxy- or 4-carboethoxy)thiazolidino, and loweralkyl bearing one or more carboxy, carboloweralkoxy, carbamoyl, acyl, sulfinyl or sulfonyl groups, or wherein B is a saturated or unsaturated loweralkylene group and K is selected from the group consisting of hydrogen, loweralkyl, loweralkoxyethyl, diloweralkyl aminoethyl, (mono- or polyhydroxy)loweralkyl, (mono- or polycarboxy)loweralkyl, (mono- or polycarb- oxy)hydroxyloweralkyl, allyl, 2,3-epoxypropyl, substituted or unsubstituted (phenyl, benzyl or 3-pyridyl) or pyridylmethyl and tetrahydropyranyl; and wherein Q, Y, m and X are defined as follows: Formula I-A) Q is m is O; X is Sa-Ta- wherein Sa is selected from the group consisting of C3-C16 cycloalkyl or C4-C17 cycloalkenyl and is either unsubstituted or substituted with at least one C1-C13 alkyl, C4-C8 cycloalkyl, decahydronaphthyl, methylene, ethylidene, or isopropylidene group; Ta is a bond or a divalent radical selected from the group consisting of unbranched or branched C,-C,3 alkylene or alkenylene and is either unsubstituted or substituted with at least one C1-C4 alkyl group; with the proviso that the total number of carbon atoms in Sa and Ta shall not exceed twenty; and with the further proviso that when Ta is not a bond, Sa is not an unsubstituted cyclopropyl nor a cyclopropyl substituted with at least one C1-C13 alkyl; Formula I-B) Q is m is O; X is Sb- wherein Sb is a branched or unbranched mono- or polyunsaturated or cyclopropylated C3-C22 alkyl group and can be represented by the formula: wherein R2 and R3 are the same or different and are hydrogen or a saturated or unsaturated C,-Cg alkyl group: R, is a: Formula I-Ba) C2 to C21 E- or Z-alkenyl group unsubstituted or substituted with at least one loweralkyl group; Formula I-Bb) C2 to C20 alkynyl group unsubstituted or substituted with at least one methyl or ethyl group; Formula I-Bc) C. to C20 alkyl group containing at least 2 non-cumulative double bonds, said group being unsubstituted or substituted with at least one methyl or ethyl group; Formula I-Bd) C3 to C,2 allenyl group unsubstituted or substituted with at least one methyl or ethyl group; Formula I-Be) vinyl or C3 to C8 E- or Z-alkenyl group said vinyl or alkenyl group being unsubstituted or substituted with at least one methyl group, and in this Formula I-Be, R2 is a vinyl or C3 to CB E- or Z-alkenyl group unsubstituted or substituted with at least one methyl group; Formula I-Bf) allyl or C. to C8 E- or Z-alkenyl group said allyl or alkenyl group being substituted with at least one exo-(methylene, ethylidene, or isopropylidene), and either further unsubstituted or substituted with at least one methyl group; Formula I-Bg) vinyl or C3 to C8 E- or Z-alkenyl group substituted between the nitrogen and the double bond with at least one loweralkenyl, said vinyl or alkenyl group being unsubstituted or substituted with at least one methyl group; Formula I-Bh) vinyl or C3 to Cs E- or Z-alkenyl group said vinyl or alkenyl group being unsubstituted or substituted with at least one methyl and in this case, R2 is a C2 to C9 alkynyl group unsubstituted or substituted with at least one methyl group; Formula I-B,) C. to C20 alkyl group containing at least one carbon-carbon double bond and at least one carbon-carbon triple bond said group being unsubstituted or substituted with at least one loweralkyl group; or wherein Sb is a; Formula I-Bj) group of the formula wherein R4 is hydrogen or a C, to C15 alkyl group unsubstituted or substituted with at least one methyl group, R5 is hydrogen or methyl and W is a bond or a C, to C15 branched or unbranched alkylene group unsubstituted or substituted with at least one methyl group; Formula I-C) Q is m is O; X is Sc-Tc- wherein Sc is selected from the group consisting of mercapto, lowerakylthio, aralkylthio, arylthio, loweralkylsulinyl, loweralkylsulfonyl, aralkylsulfinyl, aralkylsulfonyl, arylsulfinyl, arylsulfonyl, arylamino, acylamino, loweralkylsulfonylamino, arylsulfonylamino, azido, oxo. oximino, chloro, bromo, and iodo; wherein the substituent Sc may contain q carbon atoms with q being an integer from 0 to 8. inclusive: Te is an unbranched or branched alkylene group, optionally saturated or (mono- or poly-)unsaturated and containing or not containing a cycloalkyl group, represented by the formula CnH2(n-p) with n being an integer from 7 to 18, inclusive, and p being an integer from 0 to 5, inclusive, both being selected in a manner such that the sum of n and q is greater than 6 but less than 19; provided that when Sc is halogen Tc must be a saturated alkylene group; J may not be loweralkyl bearing one or more carboxy. carboloweralkoxy, carbamoyl, acyl, sulfinyl or sulfonyl groups, and Z may not be 0 II -B-C-OK; Formula I-D) Q is m is O; X is Sd-Td- wherein Sd is selected from the group consisting of substituted or unsubstituted aryl and heteroaryl groups; Td is a saturated or unsaturated alkylene group of 1-18 carbon atoms which may be branched or unbranched; such that the total number of carbon atoms in Sd and Td shall not exceed 24; provided that J may not be hydroxyl, loweralkoxy, loweralkoxyloweralkyloxy, diloweralkylaminoloweralkoxy, or substituted or unsubstituted benzyloxy; Formula I-E) Q is m is 1 to 4 inclusive; X is a saturated or unsaturated hydrocarbon radical of 7-19 carbon atoms which may be branched or unbranched and which may contain one or more radicals selected from the group consisting of saturated or unsaturated cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; Y is loweralkyl, loweralkoxy, hydroxy, nitro, acyloxy, or halo; Formula I-F) Q is a 5- or 6-membered heteroaryl ring containing one or more nitrogen, sulfur, or oxygen atoms and optionally unsubstituted or substituted with one fluoro; X is Sf-Tf- wherein Sf is selected from the group consisting of hydrogen, C3-C8 cycloalkyl, and substituted or unsubstituted aryl; Tf is a divalent radical selected from the group consisting of branched or unbranched C6-C,g alkylene, alkenylene, and alkynylene; Formula I-G) Q is m is O; X is Sg-Tg- wherein Sg is selected from the group consisting of carboxy, loweralkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, carbamyl, mono- or diloweralkyl- carbamyl, cyano, sulfo, monoalkyl- or monoarylsulfamyl; Tg is an unbranched or branched alkylene group, optionally saturated or mono- or polyunsaturated, and containing or not containing a cycloalkyl group, represented by the formula CrH2(r-p) with r being an integer from 1 to 18, inclusive, and p being an integer from 0 to 5, inclusive; with the proviso that when Sg is a carbamyl, cyano, or sulfo group, Sg and the nitrogen atom in Formula I may not be bonded to the same carbon atom of the group Tg; Formula I-H) Q is m is O; X is a saturated or unsaturated hydrocarbon radical of 7-19 carbon atoms which may be branched or unbranched and which may contain a saturated or unsaturated cycloalkyl group, said radical containing one or more perfluorinated (-CF2 or -CF3) carbon atoms excluding the carbon adjacent to the nitrogen atom; and the pharmacologically acceptable acid-addition and cationic salts thereof.

  本发明提供了一种新型氨基取代的苯基和杂环芳基化合物，这些化合物具有药学上的有用性质，特别是作为降血脂和抗动脉硬化的药物，并且提供了这些新型化合物的制备方法。新型化合物具有如下通式： Q是 其中，Y是低级烷基、低级烷氧基、羟基、硝基、酰氧基或卤素，m是0到4之间的整数(包括0和4)，或者是一个含有1个或多个氮、硫或氧原子的5-或6-元杂环芳基环，该环可能被一个氟原子取代。R是氢或在体内可转化为氢的基团；Z是： 其中，J选自羟基、低级烷氧基、低级烷氧基低级烷氧基、二低级烷基氨基低级烷氧基、氢、低级烷基、(单或多个羟基)低级烷氧基、(单或多个羧基)低级烷氧基、(单或多个羧基)羟基低级烷氧基、烯丙氧基、2,3-环氧丙氧基、取代或未取代的苯氧基、苄氧基和3-吡啶氧基、吡啶基甲氧基、四氢吡喃氧基、(单或多个羟基)低级烷基氨基、(单或多个羧基)低级烷基氨基、(单或多个羧基烷氧基)低级烷基氨基、烯丙基氨基、炔丙基氨基、2-磺乙基氨基、(取代或未取代的芳酰基)氨基、低级烷酰氨基、低级烷磺酰氨基、(取代或未取代的芳基)磺酰氨基、低级烷酰基肼基、羟胺基、多甲基亚氨基、(4-羧基或4-羧乙氧基)四氢噻唑烷基，以及一个或多个含有羧基、羧低级烷氧基、氨基甲酰基、酰基、亚砜基或砜基的低级烷基；或者 其中，B是饱和或不饱和的低级烷基亚甲基基团，K选自氢、低级烷氧基乙基、双低级烷基氨基乙基、(单或多个羟基)低级烷基、(单或多个羧基)低级烷基、(单或多个羧基烷氧基)低级烷基、烯丙基、2,3-环氧丙基、取代或未取代的(苯基、苄基或3-吡啶基)或吡啶基甲基和四氢吡喃基；并且其中Q、Y、m和X的定义如下： 通式I-A) Q是 m是0；X是Sa-Ta-，其中Sa选自C3-C16环烷基或C4-C17环烯基，并且Sa可以是未取代的或取代有一个或多个C1-C13烷基、C4-C8环烷基、十氢萘基、亚甲基、乙烯基或异丙烯基的环；Ta是一个键或选自直链或支链C1-C3烷基亚基或烯基亚基的二价基团，并且Ta可以是未取代的或取代有一个或多个C1-C4烷基的；并且，Sa和Ta中的碳原子总数不得超过20；并且进一步规定，当Ta不为键时，Sa不是未取代的环丙基，也不是取代有一个或多个C1-C13烷基的环丙基； 通式I-B) Q是 m是0；X是Sb-，其中Sb是直链或支链的单或多不饱和或环丙烷化的C3-C22烷基基团，并且可以用如下通式表示： 其中，R2和R3是相同的或不同的，它们是氢或饱和或不饱和的C1-C8烷基基团；R1是： 通式I-Ba) C2到C21 E或Z-烯基基团，未取代或取代有一个或多个低级烷基的； 通式I-Bb) C2到C20炔基基团，未取代或取代有一个或多个甲基或乙基的； 通式I-Bc) C1到C20烷基基团，含有至少2个非累积性双键，该基团未取代或取代有一个或多个甲基或乙基的； 通式I-Bd) C3到C12炔烯基基团，未取代或取代有一个或多个甲基或乙基的； 通式I-Be) 氯乙烯或C3到C8 E或Z-烯基基团，所述氯乙烯或烯基基团未取代或取代有一个或多个甲基，此时在通式I-Be中，R2是氯乙烯或C3到C8 E或Z-烯基基团，未取代或取代有一个或多个甲基的； 通式I-Bf) 烯丙基或C3到C8 E或Z-烯基基团，所述烯丙基或烯基基团在氮和双键之间被至少一个外位(甲基、乙烯基、或异丙烯基)取代，并且进一步未取代或取代有一个或多个甲基的； 通式I-Bg) 氯乙烯或C3到C8 E或Z-烯基基团，所述氯乙烯或烯基基团在氮和双键之间被至少一个低级烯基取代，所述氯乙烯或烯基基团未取代或取代有一个或多个甲基的； 通式I-Bh) 氯乙烯或C3到C8 E或Z-烯基基团，所述氯乙烯或烯基基团未取代或取代有一个或多个甲基，并且此时R2是C2到C9炔基基团，未取代或取代有一个或多个甲基的； 通式I-Bi) C1到C20烷基基团，含有至少一个碳-碳双键和至少一个碳-碳三键，所述基团未取代或取代有一个或多个低级烷基的； 或者，Sb是： 通式I-Bj) 其中，R4是氢或C1到C15烷基基团，未取代或取代有一个或多个甲基的；R5是氢或甲基；W是键或C1到C15直链或支链烷基亚甲基基团，未取代或取代有一个或多个甲基的； 通式I-C) Q是 m是0；X是Sc-Tc-，其中Sc选自巯基、低级烷基巯基、芳烷基巯基、芳基巯基、低级烷基亚砜基、低级烷基砜基、芳烷基亚砜基、芳烷基砜基、芳基亚砜基、芳基砜基、芳基氨基、酰基氨基、低级烷基砜基氨基、芳基砜基氨基、叠氮基、氧基、氧亚氨基、氯、溴和碘；其中，取代基Sc可能含有的碳原子数q是0到8之间的整数；Tc是直链或支链的烷基亚甲基基团，可以是饱和的或单或双不饱和的，并且可能含有或不含环烷基基团，用通式CnH2(n-p)表示，其中n是从7到18的整数，p是从0到5的整数，两个选择使得n和q的和大于6但小于19；并且规定，当Sc是卤素时，Tc必须是饱和的烷基亚甲基基团；并且J不能是含有一个或多个羧基、羧低级烷氧基、氨基甲酰基、酰基、亚砜基或砜基的低级烷基基团，Z不能是0—N—B—O—K； 通式I-D) Q是 m是0；X是Sd-Td-，其中Sd选自取代或未取代的芳基和杂环芳基基团；Td是含有1到18个碳原子的饱和或不饱和烷基亚甲基基团，可以是支链的或直链的；并且Sd和Td中的碳原子总数不得超过24；并且规定，J不能是羟基、低级烷氧基、低级烷氧基低级烷氧基、双低级烷基氨基低级烷氧基，或取代或未取代的苄氧基； 通式I-E) Q是 m是1到4之间的整数(包括1和4)；X是含有7到19个碳原子的饱和或不饱和的碳氢化合物基团，可以是支链的或直链的，并且可能含有一个或多个选自饱和或不饱和环烷基、取代或未取代的芳基和取代或未取代的杂环芳基的基团；Y是低级烷基、低级烷氧基、羟基、硝基、酰氧基或卤素； 通式I-F) Q是含有一个或多个氮、硫或氧原子的5-或6-元杂环芳基环，并且可能未取代或取代有一个氟原子；X是Sf-Tf-，其中Sf选自氢、C3-C8环烷基，以及取代或未取代的芳基；Tf是直链或支链C6-C8烷基亚基、烯基亚基或炔基亚基； 通式I-G) Q是 m是0；X是Sg-Tg-，其中Sg选自羧基、低级烷氧基羰基、芳氧基羰基、杂环芳氧基羰基、氨基甲酰基、单或双低级烷基氨基甲酰基、氰基、亚砜基、单烷基或单芳基磺酰氨基；Tg是直链或支链烷基亚甲基基团，可以是饱和的或单或双不饱和的，并且可能含有或不含环烷基基团，用通式CrH2(r-p)表示，其中r是从1到18的整数，p是从0到5的整数；并且规定，当Sg是氨基甲酰基、氰基或亚砜基时，Sg和通式I中的氮原子可能不与Tg上的同一碳原子键合； 通式I-H) Q是 m是0；X是含有7到19个碳原子的饱和或不饱和的碳氢化合物基团，可以是支链的或直链的，并且可能含有一个饱和或不饱和的环烷基基团，所述基团含有一个或多个全氟化的(-CF2或-CF3)碳原子，不包括与氮原子相邻的碳原子；以及其药理学上可接受的酸加成盐和阳离子盐。
• US4205085A
  申请人：——

  公开号：US4205085A

  公开（公告）日：1980-05-27